NDAORALTABLETPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WAKIX (pitolisant hydrochloride) is an oral small-molecule histamine H3-receptor antagonist approved in 2019 for narcolepsy with or without cataplexy. It works by blocking histamine H3 receptors in the brain to promote wakefulness and reduce excessive daytime sleepiness. The drug represents a novel mechanism class in narcolepsy treatment.
$0.101BPart D
Peak3.6 years to LOEAt peak lifecycle with $101M annual spending and ~8,700 Part D claims, WAKIX is in active commercial expansion phase with sustained team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
WAKIX® (Pitolisant) Pregnancy Registry
Started Aug 2021
1,329 enrolled
Pregnancy RelatedNarcolepsy
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on WAKIX at Harmony Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.